We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

CEPHEID

Develops, manufactures, and markets molecular systems and tests for institutions to perform sophisticated genetic tes... read more Featured Products: More products

Download Mobile App





Cepheid Demonstrates Advantages of PCRplus Solution at AACC 2022

By LabMedica International staff writers
Posted on 26 Jul 2022

Cepheid (Sunnyvale, CA, USA) will be demonstrating the advantages of its PCRplus Solution at the 2022 AACC Clinical Lab Expo. More...

PCRplus is an elevated PCR test category reserved for molecular diagnostic testing solutions that deliver uncompromised accuracy, speed, flexibility, simplicity, and exceptional test design expertise.

The PCRplus Solution comprises one platform and 22 IVD tests that combine accuracy, speed, flexibility, quality, and simplicity. Cepheid offers a growing portfolio of PCRplus respiratory tests that run on its 40,000 GeneXpert systems placed worldwide to deliver rapid, accurate, and actionable respiratory results. The GeneXpert System was built for simple, reference lab quality PCR testing – on location at medical centers and hospitals or closer to patient in health clinics and nursing homes. At the core of every GeneXpert System is the module (or testing bay) where a test cartridge is loaded onto the machine.

Cepheid’s line of GeneXpert Systems can be configured with a varying number of modules, or test bays, to meet the volume requirements of any setting. Smaller GeneXpert Systems are configured with two or four modules – meaning up to four different tests can be run at one time. The company’s largest GeneXpert System is configured with up to 80 modules – meaning as many as 80 tests can operate independently at any given time with a capacity of about 2,000 tests per day.

Cepheid offers CoV-2 tests that are designed with multiple gene targets to ensure comprehensive virus detection. This test design approach is used in all of Cepheid's Xpert CoV-2 tests to help guard against variants and ensure the test performance healthcare providers have come to rely on. The company has added the latest Xpert Xpress CoV-2plus test to Xpert Xpress CoV-2/Flu/RSV plus and others in its growing portfolio of PCRplus-based Xpert coronavirus tests.
 

Related Links:
Cepheid


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers identified 157 metabolites linked to BBB damage, including 25 that appeared in at least two independent studies (Image Credit: Adobe Stock)

Blood Metabolite Patterns May Enable Early Detection of Blood-Brain Barrier Injury

Early injury to the blood-brain barrier (BBB) can precede many neurological disorders but remains difficult to detect noninvasively. Laboratory markers that identify barrier dysfunction before symptoms... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.